Divestiture	12 Months Ended
Sep. 30, 2017
Discontinued Operations and Disposal Groups [Abstract]
Divestiture	Divestiture Respiratory Solutions On October 3, 2016, the Company sold a 50.1% controlling financial interest in its Respiratory Solutions business, a component of the Medical segment, to form a venture, Vyaire Medical. The Company retained a 49.9% non-controlling interest in the new standalone entity. The buyer controls the operations and governance of the new entity. The Company accounts for its remaining interest in the new entity as an equity method investment and, beginning on January 1, 2017, records its share of the new entity's earnings or losses on a one-quarter lag to Other income (expense), net. The Company has agreed to various contract manufacturing and certain logistical and transition services agreements with the new entity for a period of up to two years after the sale. Assets and liabilities held for sale on the consolidated balance sheet at September 30, 2016 included assets and liabilities subject to this agreement of approximately $578 million and $189 million, respectively. The historical financial results for the Respiratory Solutions business, which included approximately $822 million and $417 million of revenues for years ended September 30, 2016 and 2015, respectively, have not been classified as a discontinued operation.

Divestiture

Respiratory Solutions

On October 3, 2016, the Company sold a 50.1% controlling financial interest in its Respiratory Solutions business, a component of the Medical segment, to form a venture, Vyaire Medical. The Company retained a 49.9% non-controlling interest in the new standalone entity. The buyer controls the operations and governance of the new entity. The Company accounts for its remaining interest in the new entity as an equity method investment and, beginning on January 1, 2017, records its share of the new entity's earnings or losses on a one-quarter lag to Other income (expense), net. The Company has agreed to various contract manufacturing and certain logistical and transition services agreements with the new entity for a period of up to two years after the sale. Assets and liabilities held for sale on the consolidated balance sheet at September 30, 2016 included assets and liabilities subject to this agreement of approximately $578 million and $189 million, respectively. The historical financial results for the Respiratory Solutions business, which included approximately $822 million and $417 million of revenues for years ended September 30, 2016 and 2015, respectively, have not been classified as a discontinued operation.